Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zhongfeng Xingnao granule for acute cerebral hemorrhage
ChiCTR1900026276Phase 2Not yet recruiting
- Sponsor
- Chengdu University of Traditional Chinese Medicine Clinical Medical College
- Start
- Jan 2019
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Zhongfeng Xingnao granule in intracerebral hemorrhage (ICH) (2 arms), sponsored by Chengdu University of Traditional Chinese Medicine Clinical Medical College. Primary endpoints: Mortality rate and Hematoma absorption rate. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
Zhongfeng Xingnao granule
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on ChiCTR1900026276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026276.